Monday 15 June 2026

One To Watch

Spruce Biosciences

A late-stage biopharmaceutical company focused on developing novel therapies for rare endocrine disorders with significant unmet medical need.

Company Overview

Want to Update your Company's Profile?


Latest Spruce Biosciences News

Spruce Bio tanks as tildacerfont misses goals
14 March 2024
Illuminating congenital adrenal hyperplasia
3 July 2020
BRIEF—Kaken partners with Axcelead and Spruce
12 January 2023
More Spruce Biosciences news >


Today's issue

Vivoryon’s kidney reset: CEO Frank Weber on the company’s new focus
Biotechnology
Vivoryon’s kidney reset: CEO Frank Weber on the company’s new focus
15 June 2026
Pharmaceutical
Grifols launches Fesilty in USA for rare bleeding disorder
15 June 2026
Biotechnology
Elicio Thera tanks on disappointing Phase II AMPLIFY-7P study
15 June 2026
Pharmaceutical
Two-year data bolster Neurocrine’s Crenessity case in pediatric CAH
15 June 2026
Biotechnology
J&J’s Talvey combo cuts progression risk in earlier myeloma setting
15 June 2026
Pharmaceutical
Pharmstandard to build large-scale complex for production of live vaccines
15 June 2026
Biotechnology
Positive Phase III results for Intellia’s lonvo-z
15 June 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze